Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 53.1× sales vs its 3.0× historical median P/S.
Fair value ≈ $12.36 · price $221.38 today
Overvalued · 1692% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$SLS $CDTX
#1 Trending on Stocktwits
WHY IT'S TRENDING?
SELLAS Life Sciences is surging as investors interpret a recent regulatory filingwhich updates executive change-of-control agreementsas strategic preparation for a potential acquisition. This upward momentum is being further fueled by intense community discussion regarding a looming clinical catalyst and significant short-covering pressure in a stock with high borrow fees.
SLS will be # 1 Biotechnology stock BO of 2026.
Mark this post as I will be right here all the way to $240.00+ after the bidding war concludes.
I was in $CDTX when it got BO for $221.38 WITH 6 suitors in bidding war as I posted my trade here. Merck (MSD) successfully completed a $9.2 billion acquisition of Cidara, making it a subsidiary of the pharma giant. The stock last traded near $221.38 per share.
✌️🙏❤️🩹
@Palmetto_Trader As far as this Is concerned I can't complain. I scored big on $PCYC and last year on $CDTX . I am quite Happy with my 20X. But I don't invest in Trump insider trading companies like Intel. Good luck.
$CDTX $SLS Part 3. Dr. Tsirigotis one of the lead physicians treating one of the largest trial site for Regal phase 3 said at KOL October 2025 that GPS can make Bone Marrow Transplant Obsolete head on =
$3.6 Billion annually + CR1 Pre and Post BMT= $2.8 Billion + AML CR2 SOC $2.1 Billion 3 year+ maintenance $280K per year= $10 Billion+ annually before further label expansion in to 40+ other cancers = peek sale potential of $50 Billion annually by year 2030 and dethrone Keytruda as # 1 selling drug on the planet. ✌️🙏❤️🩹
$CDTX $SLS Part 2. Dr. Angelos Stergiou TD Cowen Conference: Management explicitly targets the 13,000-patient CR1 setting via NCCN Compendium guidelines. Today, 80% of CR1 patients go untreated on "Watch and Wait" because Onureg is too toxic and transplants are too dangerous for elderly patients. An HR <0.40 forces NCCN panel action. It creates a clear mandate to recommend GPS as a simple, safe off the shelf injection. ✌️🙏❤️🩹
$CDTX $SLS Last official Sellas PR was 34 days ago. I wouldn’t be one bit surprised if Sellas is already negotiating with multiple parties. I expect a bidding war after GPS Regal Pivotal Registrational phase 3 study. GPS has a priority voucher and orphan designation with FDA for AML CR2/CRp2. A potential suitor can have GPS off the shelf treatment on the market in record time. ✌️🙏❤️🩹
$CDTX $SLS I have all my shares placed for sell at LMT GTC EXT at $280.00 per share to take my emotions out of the way. I refuse to let Brokerages Borrow my shares to rescue shorts that have tried to destroy a Tiny little Biotech Co. on the cusp of a Paradigm shifting CURATIVE cancer treatment for some of the most lethal cancers on the planet.
👇 ✌️🙏❤️🩹
$SLS Something definitely leaked because the desperation of big brokerage firms offering insane rates to borrow shares from my cash accounts. Last time they behaved this way was when $CDTX got bought out by Merck for $222.00 per share LAST year. Now that’s my personal experience.
✌️🙏❤️🩹
$SLS $CDTX Trading days left in June 2026 after today. Tomorrow Markets closed for Juneteenth holiday. Dr. Angelos Stergiou has yet to PR European Impact AML SLS009 enrollment PR.
Brokerage calls remind me of $CDTX before BO at $222.00. Last Time Morgan Stanley was this aggressive to Borrow shares was right before Cidara take out by Merck! ✌️🙏❤️🩹
@Merkel Cidara $CDTX was the same I scored big on this. After a very good phaseII on influenza product,they were acquired by Merck. They also did an R/S One year an half before. It was an 1:20 reverso split From 0,55 to 11$. It was bought by Merck for more than 200$ per stare.
$SLS you have to be confident with what you are holding. Remember the days prior $CDTX bo annoucement. Sp went from 110 to 90 with no reason.
How bad is that. Selling in this range just to see sp spiking to 150 and then 220.
💎 🤚
$IVVD at this price, this is a layup. PEMGARDA is not the commercial story, and never was. And R&D higher should be expected with an impending Phase3. DECLARATION readout is everything, and PK data + what we know from the antibody via PEMGARDA infusion, it feels relatively de-risked. We should get a rise heading into data and data (which should be positive) could be a major re-rating driver. $CDTX on Phase data for flu antibody which was ~75% effective moved 300% from 400mcap to 1.2bn mcap. This is a larger phase 3 trial. Somewhat smaller market but vaccines for Covid are weaker efficacy / worse side effects vs Covid. Big upside potential and everything until data is just noise. Also not like they’re running out of cash. Should have $150M mid year, heading into the Q3 readout
